Cellino is building an ultra-scalable biomanufacturing technology stack for personalized cell, tissue, and organ replacement therapies.
Cellino has raised $25.0M in total funding. The most recent round was Grant. The last funding was announced in September 2024.
Cellino's investors include Khosla Ventures, 8VC, Felicis, The Engine, Advanced Research Projects Agency for Health.
Cellino is headquartered in Cambridge, United States.
Cellino is building an ultra-scalable biomanufacturing technology stack for personalized cell, tissue, and organ replacement therapies.
Cellino is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cellino — Funding & Investors." VCBacked, September 10, 2024, https://www.vcbacked.co/company/cellino. Accessed July 19, 2026.
VCBacked. (2024). Cellino — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/cellino
{{cite web |title=Cellino — Funding & Investors |url=https://www.vcbacked.co/company/cellino |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated